Ceftobiprole

From Wikipedia, the free encyclopedia

Ceftobiprole
Systematic (IUPAC) name
>(6R,7R)-7-[ [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2- nitroso-1-oxoethyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-3-pyrrolidinyl]- 3-pyrrolidinylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Identifiers
CAS number	?
ATC code	?
PubChem	6918430
Chemical data
Formula	C20H22N8O6S2
Mol. mass	534.568 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Intravenous

Ceftobiprole is a next generation cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and Enterococci.^[1][2][3] It was discovered by Basilea Pharmaceutica^[4] and was developed by Johnson & Johnson Pharmaceutical Research and Development.^[5] It has been shown to be statistically non-inferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.

Contents 1 Pharmacology 2 Dosing 3 Synonyms 4 References

[edit] Pharmacology

Ceftobiprole inhibits the 2a penicillin-binding protein (pbp) of Staphylococcus aureus and the 2x pbp of Streptococcus pneumoniae^[2] and is active even against methicillin-resistant Staphylococcus aureus. Ceftobiprole is resistant to staphylococcal β-lactamase.^[4]

[edit] Dosing

The adult dose of ceftobiprole is 500mg eight hourly given intravenously. Ceftobiprole cannot be given by mouth. Ceftobiprole is not licensed to be used in children,^[3] and is not currently (Feb 2008) licensed for use in the European Union or Australia. This drug is also not currently approved for use by the United States FDA (May 2008).

[edit] Synonyms

• Ro 63-9141^[4]
• BAL9141^[6]
• Ceftobiprole medocaril

[edit] References

1. ^ Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001. 
2. ^ ^{a b} Widmer A (2008). "Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin Infect Dis 46: 656–8. doi:10.1086/526528. 
3. ^ ^{a b} Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008). "A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections". Clin Infect Dis 46: 647–55. doi:10.1086/526527. 
4. ^ ^{a b c} Hebeisen P, Heinze-Krauss I, Angehrn P, et al. (2001). "In vitro and in vivo properties of Ro63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci". Antimicrob Agents Chemother 45: 825–36. doi:10.1128/AAC.45.3.825-836.2001. 
5. ^ Basilea.com
6. ^ Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002). "In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci". J Antimicrob Chemother 50: 915–932. doi:10.1093/jac/dkf249. 

v • d • e Antibacterials for systemic use: beta-lactam antibiotics - cephalosporins and related (J01D) First generation Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazolin, Cefradine, Cefroxadine, Ceftezole Second generation Cefaclor, Cefamandole, Cefmetazole, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefuroxime Third generation Cefdinir, Cefditoren, Cefetamet, Cefixime, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpiramide, Cefpodoxime, Cefsulodin, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Flomoxef, Latamoxef Fourth generation Cefepime, Cefozopran, Cefpirome, Cefquinome Fifth generation Ceftobiprole Other beta-lactam antibacterials Monobactams (Aztreonam), Carbapenems (Parenteral - Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Oral - Faropenem)